Attached files
| file | filename |
|---|---|
| EX-3.1 - EXHIBIT 3.1 - AYTU BIOPHARMA, INC | v441568_ex3-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): June 1, 2016
| AYTU BIOSCIENCE, INC. | ||
| (Exact Name of Registrant as Specified in Charter) | ||
| Delaware | 000-53121 | 47-0883144 |
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| 373 Inverness Parkway, Suite 206, Englewood, Colorado | 80112 | |
| (Address of Principal Executive Offices) | (Zip Code) | |
Registrant’s Telephone Number, Including Area Code: (720) 437-6580
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 5.03. | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. |
On June 1, 2106, we filed a certificate of amendment with the Delaware Secretary of State for the purpose of amending our certificate of incorporation to decrease the number of shares of common stock the Company has the authority to issue from 300,000,000 shares to 100,000,000 shares. This amendment was described in our definitive proxy statement for our annual meeting of shareholders held on May 24, 2016 and was approved by our shareholders at the annual meeting. We reported the voting results from the annual meeting in a Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 25, 2016.
| Item 9.01. | Financial Statements and Exhibits |
| (d) | Exhibits. |
| Exhibit No. |
Description of Exhibit
|
| 3.1 | Certificate of Amendment of Certificate of Incorporation of Aytu Bioscience, Inc., effective June 1, 2016. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: June 2, 2016 | AYTU BIOSCIENCE, INC. |
| /s/ Gregory A. Gould | |
| Name: Gregory A. Gould | |
| Title: Chief Financial Officer |